<DOC>
	<DOC>NCT00110916</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical response in subjects with symptomatic OA of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular (IA) injection.</brief_summary>
	<brief_title>Treatment for Patients With Osteoarthritis (OA) of the Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria Pain defined by a level of greater than 30 mm on a 100 mm Visual Analogue Scale (VAS) No evidence of active effusion or inflammatory flare, confirmed by investigator Must exhibit radiographic evidence of tibiofemoral compartment knee OA within 12 months of screening Stable doses of any nonprescribed supplements (e.g. glucosamine or chondroitin sulphate, shark cartilage, diacerhein, soya extract) for at least 2 months prior to screening Unchanged use of physical therapy, biomechanical devices or orthotic support within at least 2 months of screening Subjects on nonsteroidal antiinflammatory drug (NSAID) therapy must discontinue NSAIDs 3 days prior to baseline (Day 1) Before any studyspecific procedure is performed, the appropriate written informed consent for participation in the study must be obtained Malignancy within the previous 5 years, except for basal cell or in situ cancer Significant hematologic disease Active infection or history of recurrent or chronic infections Known diagnosis of HIV, hepatitis B, or hepatitis C infection Uncontrolled diabetes or cardiovascular disease and hypertension Inflammatory arthropathy including secondary OA Isolated OA of the patellofemoral joint (bi or tricompartmental involvement are not exclusions) Endstage ("boneonbone") OA (Kellgren Lawrence score of 4) OA of the hip ipsilateral to the index knee Total white cell count less than 2.0 x 109/L and/or platelet count less than 100 x 109/L observed within 1 month preceding screening Prior IA injection of anakinra or experimental interleukin1 (IL1) inhibitor therapy Concurrent treatment with subcutaneous (SC) anakinra Concurrent or recent (less than or equal to 1 month) use of experimental therapy Prior IA corticosteroid injection within 1 month of study Prior viscosupplement therapy within 3 months of study Contraindication(s) to IA injections Subjects who are pregnant or breastfeeding, or plan to become pregnant during the study Subject is not using adequate contraception Known allergy to E coliderived products Unable to understand informed consent Concerns regarding subject's compliance with the protocol procedures Subject will not be available for followup assessment Active substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Intra-articular</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>OA</keyword>
	<keyword>anakinra</keyword>
	<keyword>Amgen</keyword>
</DOC>